# NCT06448312 (NCT06448312)

> A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06448312
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: SKB264; Pembrolizumab
- Enrollment: 406
- Primary outcome: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06448312